Modulation of the opioid growth factor ([Met 5]-enkephalin)- opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck

Head and Neck

Volumn 34, Issue 4, 2012, Pages 513-519

  McLaughlin, Patricia J ^a   Stucki, Jaimon K ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Met 5 enkephalin; cancer; cell proliferation; imiquimod; low dose; naltrexone

Indexed keywords

GROWTH FACTOR; IMIQUIMOD; METENKEPHALIN; NALTREXONE; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ACTIVITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

AMINOQUINOLINES; ANALYSIS OF VARIANCE; ANIMALS; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECEPTORS, OPIOID; REFERENCE VALUES; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN; UP-REGULATION;

EID: 80052798281     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21759     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics. CA Cancer J Clin 2010; 59: 225-249.
2. Garcia M, Jemal A, Ward EM, et al. Global cancer facts and figures 2007. Atlanta, GA: American Cancer Society; 2007.
3. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
4. Neville BW, Day TA,. Oral cancer and precancerous lesions. CA Cancer J Clin 2002; 52: 195-215.
5. Shirai K, O'Brien PE,. Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol 2007; 8: 239-251.
6. Haddad R, Annino D, Tishler RB,. Multidisciplinary approach to cancer treatment: focus on head and neck cancer. Dent Clin North Am 2008; 52: 1-17.
7. Yao M, Epstein JB, Modi BJ, Pytynia KB, Mundt AJ, Feldman LE,. Current surgical treatment of squamous cell carcinoma of the head and neck. Oral Oncol 2007; 43: 213-223. (Pubitemid 46228018)
8. Lorch JH, Posner MR, Wirth LJ, Haddad RI,. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin N Am 2008; 22: 1155-1163.
9. Marur S, Forastiere AA,. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008; 83: 489-501. (Pubitemid 351536473)
10. Zagon IS, Verderame MF, McLaughlin PJ,. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 2002; 38: 351-376. (Pubitemid 34219111)
11. Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE,. Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst 1987; 79: 1059-1065. (Pubitemid 17165277)
12. 5]-enkephalin, and the zeta opioid receptor in head and neck squamous cell carcinoma. Laryngoscope 1997; 197: 335-339.
13. McLaughlin PJ, Levin RJ, Zagon IS,. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol 1999; 14: 991-998.
14. McLaughlin PJ, Levin RJ, Zagon IS,. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett 2003; 199: 209-217. (Pubitemid 37297714)
15. McLaughlin PJ, Stack BC Jr, Levin RJ, Fedok F, Zagon IS,. Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck. Cancer 2002; 97: 1701-1710.
16. McLaughlin PJ, Stack BC Jr, Braine KM, Ruda JD, Zagon IS,. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. Int J Oncol 2004; 24: 227-232.
17. Jaglowski JR, Zagon IS, Stack BC, et al. Opioid growth factor (OGF) enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2005; 56: 97-104. (Pubitemid 41201762)
18. McLaughlin PJ, Jaglowski JR, Verderame MF, Stack BC, Leure-duPree AE, Zagon IS,. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int J Oncol 2005; 26: 809-816.
19. McLaughlin PJ, Verderame MF, Hankins JL, Zagon IS,. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med 2007; 19: 421-428.
20. McLaughlin PJ, Kreiner S, Morgan CR, Zagon IS,. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor. Int J Oncol 2008; 33: 751-757.
21. Zagon IS, Donahue RN, McLaughlin PJ,. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1154-R1161.
22. Urosevic M, Oberholzer PA, Maier T, et al. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Clin Cancer Res 2004; 10: 4959-4970. (Pubitemid 39099769)
23. 5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol 2010; 299: R774-R785.
24. Cheng F, McLaughlin PJ, Zagon IS,. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin β and Ran for nucleocytoplasmic trafficking. Exp Biol Med 2010; 235: 1093-1101.
25. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ,. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res 2007; 67: 10511-10518. (Pubitemid 350070827)
26. Zagon IS, McLaughlin PJ,. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Int J Oncol 2004; 24: 1443-1448.
27. Zagon IS, McLaughlin PJ,. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 2003; 37: 79-88. (Pubitemid 37421490)
28. Zagon IS, McLaughlin PJ,. Opioid growth factor, opioids, and differentiation of human cancer cells. Neuropeptides 2005; 39: 495-505. (Pubitemid 41443526)
29. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS,. Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp Biol Med 2009; 234: 532-541.
30. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ,. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med 2008; 233: 968-979.
31. Zagon IS, McLaughlin PJ,. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 2003; 37: 79-88. (Pubitemid 37421490)
32. Zagon IS, McLaughlin PJ,. Opioid growth factor, opioids, and differentiation of human cancer cells. Neuropeptides 2005; 39: 495-505. (Pubitemid 41443526)
33. Zagon IS, Rahn KA, McLaughlin PJ,. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides 2007; 41: 441-452. (Pubitemid 350101823)
34. Zagon IS, McLaughlin PJ,. Naltrexone modulates tumor response in mice with neuroblastoma. Science 1983; 221: 671-673. (Pubitemid 13026087)
35. Zagon IS, McLaughlin PJ,. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci 1984; 35: 409-416. (Pubitemid 14083762)
36. Zagon IS, McLaughlin PJ,. Stereospecific modulation of tumorigenicity by opioid antagonists. Eur J Pharmacol 1985; 113: 115-120. (Pubitemid 15246187)
37. Zagon IS, Gibo DM, McLaughlin PJ,. Ontogeny of zeta (ζ), the opioid growth factor receptor, in the rat brain. Brain Res 1992; 596: 149-156.
38. 5]- enkephalin to acute opioid antagonist (naltrexone) exposure. Mol Brain Res 1995; 33: 111-120.
39. Eklind J, Tartler U, Maschke J, Llidbrink P, Hengge UR,. Imiquimod to treat different cancers of the epidermis. Dermatol Surg 2003; 9: 890-896. (Pubitemid 36927519)
40. McLaughlin PJ, Rogosnitzky M, Zagon IS,. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors. Exp Biol Med 2010; 235: 1292-1299.
41. Smith JP, Conter RL, Bingaman SI, et al. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anti-Cancer Drugs 2004; 15: 203-209. (Pubitemid 38429411)
42. Smith JP, Stock H, Bingaman S, Mauger DT, Zagon IS,. Low dose naltrexone therapy improves Crohn's disease. Am J Gastroenterol 2007; 102: 820-828. (Pubitemid 46496605)
43. Smith JP, Bingaman SI, Mauger DT, Harvey HA, Demers LM, Zagon IS,. Opioid growth factor (OGF) improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clin Trials 2010; 2: 37-48.